Loading organizations...
§ Private Profile · 11099 North Torrey Pines Rd Suite 290, La Jolla, CA 92037, United States
Biotechnology company developing precision medicines for autoimmune neuropsychiatric diseases, blocking autoantibodies in the brain.
Based in La Jolla, California, Arialys Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines to treat autoimmune neuropsychiatric diseases by blocking pathogenic autoantibodies in the brain. The biotechnology firm focuses on central nervous system disorders, with its lead therapeutic antibody candidate, ART5803, targeting conditions such as anti-NMDA receptor encephalitis and autoimmune dementia. The pre-commercial enterprise officially emerged from stealth mode in September 2023 after securing $58 million in seed financing from a syndicate of venture capital backers including Johnson & Johnson Innovation, MPM BioImpact, and Alexandria Venture Investments. Arialys acquired the exclusive worldwide rights to its primary compound from Astellas Pharma and recently received Orphan Drug Designation from the United States FDA. The clinical organization was founded in 2021 by scientific founder Mitsuyuki Matsumoto alongside founding investors Avalon BioVentures and Catalys Pacific.
Arialys Therapeutics has raised $58.0M across 1 funding round.
Arialys Therapeutics has raised $58.0M in total across 1 funding round.
Arialys Therapeutics has raised $58.0M in total across 1 funding round.
Arialys Therapeutics's investors include Avalon Ventures, Alexandria Venture Investments, Jay Lichter, Catalys Pacific, Johnson & Johnson Innovation, MPM Capital.
Arialys Therapeutics has raised $58.0M across 1 funding round. Most recently, it raised $58.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $58M Seed | — | Avalon Ventures, Alexandria Venture Investments, JAY Lichter, Catalys Pacific, Johnson & Johnson Innovation, MPM Capital | Announced |
Arialys Therapeutics is a clinical-stage biotechnology company developing precision medicines targeting autoimmune mechanisms in neuropsychiatric diseases.[2][1] Founded in 2021 and emerging from stealth in 2023, it focuses on its lead candidate ART5803, a therapeutic antibody that blocks pathogenic autoantibodies against the NMDA receptor (NMDAR) to treat conditions like anti-NMDAR encephalitis (ANRE), autoimmune psychosis, schizophrenia, dementia, and related disorders.[2][3][5] The company serves patients with rare and severe CNS disorders where autoantibodies disrupt brain function, addressing a critical gap in treatments by rescuing NMDAR activity and reversing neuropsychiatric symptoms, backed by $58 million in seed funding from Avalon BioVentures, Catalys Pacific, and MPM Capital.[1][4] As of mid-2025, ART5803 has shown compelling preclinical data published in *Nature Communications* and is advancing toward Phase 1 trials, with GLP tox studies completed and clinic entry anticipated soon.[3][6][5]
Arialys was established in 2021 by venture firms Catalys Pacific, Avalon BioVentures, and MPM Capital to advance an asset acquired from Astellas Pharma, Japan's second-largest pharmaceutical company.[1][3] The core technology originated from Mickey Matsumoto, Arialys's founding scientist and CSO, who spent 32 years at Astellas leading its Neuroscience Research Unit and developing the program before Astellas exited CNS due to other failures and licensed it out.[1][3] Catalys Pacific orchestrated the company creation, assembling global experts in immunology, neurology, and pharma to explore autoimmune neuropsychiatry—a field ignited by the 2007 discovery of brain-targeting autoantibodies, particularly against NMDAR.[2][1] Early traction included a $58 million seed round in September 2023 upon launch, recognition as a top innovative startup, and preclinical validation leading to *Nature Communications* publication in June 2025.[4][3][6]
Arialys stands out in autoimmune neurology through:
Arialys rides the wave of autoimmune neuropsychiatry, a paradigm shift since 2007 recognizing brain-targeted autoantibodies as drivers of severe CNS disorders previously misdiagnosed as primary psychiatric issues.[2] This aligns with surging interest in precision immunology for neurology, fueled by advances in structural biology and antibody engineering amid a biotech boom in CNS rare diseases.[1][6] Market tailwinds include regulatory incentives for orphan indications like ANRE, growing recognition of NMDAR's role in schizophrenia/dementia (affecting millions), and Big Pharma's (e.g., Astellas) strategic exits creating in-licensing opportunities.[3][1] By pioneering brain-specific autoantibody blockers, Arialys influences the ecosystem, validating "NewCo" models for transpacific asset spins and accelerating therapies where current options fail, potentially reshaping treatment for 10-30% of psychosis cases with autoimmune roots.[2][1]
Arialys is poised for Phase 1 readouts in 2026 with ART5803, potentially validating it as a first-in-class therapy and unlocking expansion into larger indications like autoimmune schizophrenia.[5][6] Key trends—AI-driven antibody design, orphan drug fast-tracks, and immunology-neurology convergence—will propel growth, with partnerships (e.g., J&J Innovation) amplifying scale.[1] Its influence could evolve from niche CNS innovator to category leader, bridging Japanese pharma assets with U.S. biotech via models like Catalys Pacific's, ultimately delivering breakthroughs where autoimmunity meets the mind.[1][3] This positions Arialys as a high-momentum bet in precision neuropsychiatry.